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Abstract
The cluster randomized trial (CRT) is used increasingly in knowledge translation research, quality improvement
research, community based intervention studies, public health research, and research in developing countries.
However, cluster trials raise difficult ethical issues that challenge researchers, research ethics committees, regulators,
and sponsors as they seek to fulfill responsibly their respective roles. Our project will provide a systematic analysis
of the ethics of cluster trials. Here we have outlined a series of six areas of inquiry that must be addressed if the
cluster trial is to be set on a firm ethical foundation:
1. Who is a research subject?
2. From whom, how, and when must informed consent be obtained?
3. Does clinical equipoise apply to CRTs?
4. How do we determine if the benefits outweigh the risks of CRTs?
5. How ought vulnerable groups be protected in CRTs?
6. Who are gatekeepers and what are their responsibilities?
Subsequent papers in this series will address each of these areas, clarifying the ethical issues at stake and, where
possible, arguing for a preferred solution. Our hope is that these papers will serve as the basis for the creation of
international ethical guidelines for the design and conduct of cluster randomized trials.
Introduction
The cluster randomized trial is an increasingly important
method in health research. Cluster trials randomize intact
social units, such as households, primary care practices,
hospital wards, classrooms, neighborhoods and entire
communities, to differing intervention arms. Research
interventions in cluster trials may be directed at the entire
cluster or at individual cluster members. Compared with
an individually randomized trial with the same number of
individuals, cluster trials are inefficient and have less statis-
tical power [1]. This is a result of the fact that the
responses of individuals within a cluster tend to be more
similar than the responses of individuals in differing clus-
ters [1]. Accordingly, the use of a cluster randomized
design must be carefully justified. The cluster randomized
design is used appropriately in a number of circumstances.
First, the nature of the intervention may require that it
be administered at the cluster level. For instance, the
Community Intervention Trial for Smoking Cessation
(COMMIT) used mass education – a cluster-level inter-
vention – to target entire communities in an attempt to
reduce smoking rates. The trial promoted smoking cessa-
tion through a wide range of influences including public
education, health care workers, and employers and with
such broad interventions, randomization of individuals
would have been impossible [2].
Second, interventions may involve training or educa-
tion of health professionalsw i t ht h ea i mo fi m p r o v i n g
patient care. For example, Lewin and colleagues exam-
ined the impact on patient outcomes of a cluster-level
training programme for health workers caring for tuber-
culosis patients in South Africa [3]. The study targeted
primary care clinics in Cape Town that had tuberculosis
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any medium, provided the original work is properly cited.treatment completion rates of less than 70%. In the inter-
vention arm of the trial, nurse clinicians underwent an
18 hour in-service training program that focused on
patient centered care and quality improvement. Study
outcomes compared patient treatment completion and
patient cure rates before and after the study intervention.
Here again, an intervention targeting a provider who
treats many patients often makes patient-specific rando-
mization unfeasible or impossible.
Third, the investigators may desire to reduce the effect
of treatment contamination. For instance, Kennedy and
colleagues studied the effect of patient-centered educa-
tional materials – an individual-level intervention – on
patient knowledge, anxiety, and quality of life [4].
Patients in the study were on long term follow-up for
ulcerative colitis. As patients attending the same hospital
clinic frequently interact with one another, the study
randomized clusters of patients attending the same
clinic to receive the educational materials or no inter-
vention to avoid treatment contamination.
Fourth, investigators may wish to study both indivi-
dual and group effects of an intervention. For example,
vaccine researchers have employed cluster randomized
trials to quantify both the direct and indirect effects of
vaccination [5]. A vaccine administered to individuals
within a community may directly protect an individual
from infection by inducing protective antibodies or
indirectly by virtue of the fact the person is surrounded
by people who have developed protective antibodies to
the disease (so-called “herd immunity”). A cluster ran-
domized trial allows researchers to measure the protec-
tive effect of the vaccine both among those who are
vaccinated and develop antibodies and in the commu-
nity at large.
The literature exploring the design, analysis, and
reporting of cluster randomized trials is expanding
rapidly [6,7]. But cluster trials raise difficult ethical issues
that have not been addressed adequately. A Canadian
Institutes of Health Research funded project seeks to
study ethical issues in health-related cluster randomized
trials systematically to inform the development of inter-
national guidelines. As described elsewhere, the project
involves three major components [8]. First, it seeks to
document current practice through a systematic review
of cluster trials, in-depth interviews with cluster rando-
mization trialists, a survey of research ethics committees,
focus group discussions, and in-depth interviews with
trial participants and gatekeepers. Second, it aims to ana-
lyze comprehensively the ethical issues posed by cluster
trials in a series of papers. Third, and finally, the project
will convene an expert panel to develop guidelines for
the ethical conduct and review of cluster trials.
This article introduces a series of papers from the sec-
ond part of the larger project that explore ethical issues
in health-related cluster randomized trials. In this paper,
we explain the importance of ethical issues in cluster
trials, review contemporary principles of research ethics,
and define a series of ethical issues posed by cluster
trials. Each of these issues is addressed in detail in a
subsequent paper in the series.
Importance of the problem
While there is a small but growing literature on the sub-
ject, the ethical issues raised by cluster randomized trials
require further analysis. As a result, researchers currently
lack authoritative guidance to help them design and con-
duct cluster trials according to the highest ethical stan-
dards. Research ethics committees and regulators have
no single international standard to guide their review of
cluster trials. Predictably, the lack of authoritative gui-
dance has resulted in uncertainty and markedly different
interpretations as to permissible practices in cluster trials.
Consider the experience with two knowledge translation
studies, the NEXUS trial conducted in the UK and the
Keystone study in the United States.
In the NEXUS trial, Eccles and colleagues used a 2 × 2
factorial, cluster randomized design to study the effect of
two interventions on general practitioners’ use of radio-
graphs [9]. In the study, 244 primary care practices in
England and Scotland were randomly allocated to no
intervention, audit and feedback, educational messages,
or both in an attempt to reduce general practitioner
requests for lumbar spine and knee radiographs in accord
with UK Royal College of Radiologists’ guidelines. Audit
and feedback reports were shared with practices at base-
line and six months and compared the number of
requests for radiographs within the practice with all
other practices in the previous six months. Educational
messages were attached to reports of radiographs ordered
during the 12 month intervention period. The outcome
measure, using data routinely collected by radiology
departments, was the number of each kind of radiograph
request per 1000 patients registered with each practice.
The trial concluded that educational messages reduced
radiography referral requests by 20%, but found that
audit and feedback had no impact on referral requests.
The NEXUS trial was approved by the West Midlands
Multi-site Research Ethics Committee. Although the
study interventions targeted general practitioners,
informed consent was not obtained from them. Else-
where, the study authors explain that
“we successfully argued that the trial interventions
were the equivalent of low risk service developments
and that the requirement to seek consent from all
potential healthcare professionals may make the
project unfeasible or bias our assessment of the study
outcome. As a result, we informed all general
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ongoing trial but did not explicitly seek their consent.
When the interventions were rolled out, we received
f e w e rt h a nf i v ec o m p l a i n t sf r o mo v e r1 , 0 0 0g e n e r a l
practitioners involved in the study” [10].
Furthermore, although the study sought to change the
management of patients presenting with knee and lower
back pain, informed consent was not sought from
patients treated in the general practices participating in
the study. The study authors argued that patients indir-
ectly affected by the study intervention could not be
identified at the time of randomization and it would be
difficult or impossible to respect patient refusals. “If a
patient decided that they [sic] did not want to receive
care influenced by the intervention, how can the general
practitioner minimize the influence of the intervention
for the individual patient” [10]? The NEXUS trial is
regarded as a model knowledge translation study and has
been cited numerous times in the literature.
Compare the NEXUS trial with recent experience by the
Michigan Health and Hospital Association Keystone Inten-
sive Care Unit study (hereafter, the “Keystone Study”).
While the Keystone Study was not a cluster randomized
trial (it lacked randomization and a concurrent control
group), it involved the administration of a knowledge
translation intervention to health professionals and
observed patient outcomes. The Keystone Study is
described as a prospective cohort study involving 103
intensive care units that sought to reduce the rate of blood-
stream infections resulting from central venous catheters
[11]. A complex intervention targeted health professionals’
use of procedures known to reduce catheter-related infec-
tions. The intervention included education of healthcare
providers, the creation of a central line cart with needed
supplies, a checklist to ensure adherence with procedures,
stopping providers if they were not adhering to procedures,
and routine discussion of catheter removal. Data on the
number of catheter-days and catheter-related infections
were collected and aggregated into three-month periods at
baseline, during the intervention period, and for up to 18
months of follow up. The study results were impressive.
Catheter-related bloodstream infection dropped from 2.7
infections per 1000 catheter-days at baseline to 0 three
months after the intervention and remained low for the
duration of follow up. If widely implemented, the complex
intervention could cut catheter-related infection rates by
half [12].
Like the NEXUS trial, the Keystone study was approved
by a single research ethics committee, in this case, the
institutional review board at Johns Hopkins University.
The institutional review board determined that the study
was exempt from federal regulations on the basis that it
involved “the collection or study of...[information]
recorded by the investigator in such a manner that sub-
jects cannot be identified” [13]. Accordingly, the institu-
tional review board did not require researchers to obtain
the informed consent of health care providers or patients
in the study. Shortly after the publication of the Keystone
study, the U.S. Office for Human Research Protections
(OHRP) – the government agency that oversees institu-
tional review boards in the U.S. – received an anonymous
complaint that the Keystone study had not been con-
ducted in accord with federal regulations [14]. The
OHRP investigation found that the institutional review
board at Johns Hopkins University erred in considering
the study exempt from federal regulations, institutional
review board review should have been conducted at all
participating sites, and that informed consent should
have been obtained from both the health professionals
and the patients (or their surrogates) in the study. As a
result, the Keystone study was suspended and the conti-
nuing collection of follow-up data was halted.
The conflicting experiences of the NEXUS trial and the
Keystone study reveal deep disagreements on basic ethi-
cal issues. For instance: When is a study human subjects
research? Who is a research subject? And from whom,
h o w ,a n dw h e nm u s ti n f o r m e dc o n s e n tb eo b t a i n e d ?
Until these questions can be answered, uncertainty will
remain. According to Kass and colleagues, the “moral
hazard of this uncertainty is that fewer formal patient
safety studies may be undertaken, resulting in a slow-
down in progress...” [15].
A standard view of research ethics
We begin our exploration of ethical issues posed by cluster
randomized trials by considering a standard view of
research ethics. Our current understanding of the ethics of
clinical research is largely based on individually rando-
mized trials. Typically, in these trials the research subject
is simultaneously the unit of randomization, the unit of
experimentation, and the unit of observation. Commonly,
a patient is allocated randomly to receive one of two dif-
fering treatment regimens and data documenting the
patient’s response to the treatment received are recorded.
Because such studies target individuals, the ethics of clini-
cal research is focused on the protection of the liberty and
welfare interests of individual research subjects. Liberty
interests include a right of freedom from interference
without informed consent and a right of confidentiality.
Welfare interests include the interest to receive treatment
consistent with competent medical care, and the interest
not to be exposed to undue risk for the benefit of third
parties.
According to Levine, “[t]he term ‘research’ refers to a
class of activities designed to develop or contribute to
generalizable knowledge” [16]. Research ethics may be
viewed as governed by four ethical principles: respect
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munities [16,17]. The principle of respect for persons
requires that researchers take seriously the choices of
autonomous people, that is, people who can responsibly
make their own decisions. Importantly, people lacking
autonomy, such as young children or adults with
advanced dementia, are entitled to protection. The prin-
ciple of respect for persons is the source of the moral
rules of informed consent and confidentiality (table 1).
The researcher is generally obligated to obtain agree-
ment from a research subject (or his or her surrogate
decision maker) for study participation. In order for
informed consent to be valid, the research subject must
have the cognitive capacity to make the choice, be so
situated as to choose freely, have adequate information,
and understand what is at stake in the decision.
Informed consent may not be required when it cannot
p r a c t i c a b l yb eo b t a i n e da n ds t u d yp a r t i c i p a t i o np o s e s
only minimal risk. Researchers must also take necessary
steps to protect the confidentiality of the research sub-
ject’s health information.
The principle of beneficence obliges researchers not to
harm needlessly and, where possible, to promote the good
of research subjects. Clinical research often contains a
mixture of study procedures, some offering reasonable
prospect of benefit to research subjects (therapeutic proce-
dures), while others are administered solely to answer the
scientific question (nontherapeutic procedures). According
to a systematic approach to the ethical analysis of benefits
and harms in research called component analysis, thera-
peutic and nontherapeutic procedures must be considered
separately [18]. Therapeutic procedures, such as drugs or
surgical procedures, are justified if they satisfy clinical
equipoise, meaning they must be comparable with compe-
tent medical care. In other words, there must be a state of
honest, professional disagreement in the community of
expert practitioners as to the preferred treatment [19].
Non-therapeutic procedures, such as additional blood
tests or questionnaires that are not clinically indicated, do
not offer the prospect of benefit to research subjects. Non-
therapeutic procedures are acceptable if the risks asso-
ciated with them are minimized consistent with sound
scientific design, and reasonable in relation to the knowl-
edge to be gained. When the study involves a vulnerable
population, such as children or incapable adults, the risks
posed by nontherapeutic procedures must not exceed a
minor increase above minimal risk. According to compo-
nent analysis, one may only conclude that the benefits and
harms of a study are acceptable when the moral rules
for both therapeutic and non-therapeutic procedures are
satisfied (table 1).
The principle of justice may be defined as the ethical
obligation to distribute the benefits and burdens of
research fairly. Researchers have an obligation to ensure
that study procedures for the selection of research sub-
jects are equitable. Researchers must neither exploit the
vulnerable, nor exclude without good reason those who
stand to benefit from study participation. In order for
proposed eligibility criteria to be evaluated, each criterion
must be accompanied by a clear justification in the study
protocol [20]. The inclusion of a vulnerable group (such
as children, incapable adults, prisoners, or pregnant
women) requires a clear justification. Further, in so far as
is possible and practicable, the study population ought to
mirror the target clinical population. The historical
exclusion – in certain cases – of children, women, and
racial minorities from the benefits of research has led to
a variety of contemporary initiatives to promote their
inclusion in clinical research [21,22]. The principle of
justice also requires that provisions be in place to com-
pensate research subjects who are harmed as a result of
research participation [23].
A novel ethical principle of respect for communities has
been proposed [24]. The principle of respect for commu-
nities implies that investigators have an obligation to
respect communal values, protect and empower social
institutions, and, where applicable, abide by the decisions
of legitimate communal authorities. There is much sup-
port for the principle. First, the community (or commu-
nities) to which we belong is an important source of
values and self-understanding. Second, a community con-
sists of social structures that are essential to the well-being
of its members. Third, the principle acknowledges that
some communities already exercise power legitimately to
Table 1 Ethical principles and rules for the conduct of clinical research. (Adapted from [17])
Moral Principle Moral Rule
Respect for persons Obtain the informed consent of prospective research subjects (or their surrogate decision makers).
Protect the confidentiality of private information.
Beneficence Therapeutic procedures must satisfy clinical equipoise.
Risks of non-therapeutic procedures must be (1) minimized and (2) reasonable in relation to knowledge to be gained.
Justice Subject selection procedures must be fair.
Compensate subjects harmed as a result of research participation.
Respect for communities Respect communal values, and protect and empower social institutions.
Where applicable, abide by the decisions of legitimate communal authority.
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in the collection of taxes or the setting of speed limits on
roads. Practically, the researcher-community relationship
ought to be viewed as a partnership in which community
partners are involved from study design through publica-
tion [25].
Ethical issues posed by cluster trials
Cluster randomized trials only partly fit within the cur-
rent paradigm of research ethics. They pose difficult ethi-
cal issues for two basic reasons. First, cluster trials
involve groups rather than (merely) individuals, and our
understanding of the moral status of groups is incom-
plete. As a result, the answers to pivotal ethical questions,
such as who may speak on behalf of a particular group
and on what authority they may do so, are unclear.
Second, in cluster trials the units of randomization,
experimentation, and observation may differ, meaning,
for instance, that the group that receives the experimen-
tal intervention may not be the same as the group from
which data are collected (e.g., in the NEXUS trial, the
intervention was directed at primary care physicians and
the outcome was the frequency of patient x-rays). The
implications for the ethics of trials of experimental inter-
ventions with (solely) indirect effects on patients and
others is currently not well understood. Based on review
of the literature, interviews with cluster randomization
trialists, the practical experiences of team members, and
group discussion, members of the CIHR funded project
identified six ethical areas of inquiry related to cluster
trials in need of further exploration and analysis. Below
we introduce each of these ethical issues. Subsequent
papers in the series will address in detail each of these
domains of inquiry.
1. Who is a research subject?
To determine whether the ethical principles and regula-
tions governing research apply, one must first conclude
that a study is human subjects research and then identify
the research subjects. Indeed, much of the debate on the
Keystone study focused on whether the study was in fact
human subjects research [14,26-28]. For instance, Baily
argued that the Keystone study is not human subjects
research:
“The project was not designed to use ICU patients as
human subjects to test a new, possibly risky method
of preventing infections; rather, it was designed to
promote clinicians’ use of procedures already known
to be safe and effective for the purpose. Each hospital
engaged in a classic quality-improvement activity in
which team members worked together to introduce
best practices and make them routine, with quantita-
tive feedback on outcomes being intrinsic to the
process. Such activities should not require IRB
review.” [26].
But neither novelty nor risk is at the core of what con-
stitutes human subjects research. Rather, recalling
Levine’s definition of research above, research is a sys-
tematic intervention designed to produce generalizable
knowledge. Miller and Emanuel argue that “the project
was...[human subjects research] since it prospectively
implemented a protocol of infection control interven-
tions and tested hypotheses regarding its effectiveness.
Publication of the study results suggests that a goal was
to produce generalizable results” [14].
While the line between quality improvement activities
and human subjects research can be very difficult to
draw [29], we believe the distinction is rarely an issue for
cluster randomized trials. Thed i f f i c u l ti s s u ef o rc l u s t e r
trials is to establish who counts as a research subject.
The question is of considerable importance, as only
research subjects properly fall under the aegis of research
ethics committees and protections such as informed con-
sent. Knowledge translation cluster trials commonly
intervene on healthcare providers but measure outcomes
on patients. Are the healthcare providers research sub-
jects in this case? What about the patients? Other cluster
trials, such as the COMMIT study, involve community
level interventions and collect data on a subset of com-
munity members. Are just those who were sampled for
data research subjects, or are all members of the commu-
nity research subjects?
U.S. regulations define a research subject as a “living
individual about whom an investigator...conducting
research obtains (1) Data through intervention or inter-
action with the individual, or (2) Identifiable private
information”.I tg o e so nt od e f i n e‘interventions’ as “both
physical procedures by which data are gathered...and
manipulations of the subject or the subject’s environment
that are performed for research purposes” [30]. With
respect to knowledge translation trials, when healthcare
workers are the target of the study intervention it might
be argued that they are, as a result, research subjects. But
in such studies, if patients are only indirectly impacted by
the study intervention and if no identifiable private infor-
mation is collected, should we consider them research
subjects? (This, we take it, might be a better way of
understanding Baily’s point about the Keystone study.)
What about community members in a cluster trial in
which the intervention is applied at the level of the com-
munity? The answer depends on how we understand the
phrase “manipulations of...the subject’s environment”
[31]. To identify who is a research subject in cluster
trials, we need a clear understanding of what sorts of
environmental manipulations properly invoke the protec-
tive apparatus of research ethics and regulation. Each of
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2. From whom, how, and when must informed consent
be obtained?
The ethical principle of respect for persons generally
requires that researchers obtain the informed consent of
research subjects. In the cluster trials literature it is
commonly claimed that the need for informed consent
from individuals depends on whether the study inter-
vention is delivered at the level of the cluster or the
individual [32,33]. With a cluster-level intervention,
individual refusal of informed consent may be, in effect,
rendered meaningless. If an individual within a cluster
refuses study participation he or she will, in many cases,
be unable to avoid exposure to the study intervention
and this undermines the very purpose of consent [33].
As Edwards and colleagues put it, in such studies, “the
autonomy principle is lost except insofar as the indivi-
dual has any democratic choice of who the guardian is
and some right to consultation by the guardian” [32].
When the intervention targets individual research sub-
jects, generally informed consent can and should be
obtained. In these cases, “it is only trial entry that takes
place without individual consent, as the individual treat-
ments offered can be declined or accepted by each parti-
cipant. This resembles a conventional trial where
consultation over consent implies that available alterna-
tives are offered and that these always include routine
care” [32].
While this approach seems broadly correct, further work
will need to justify in terms familiar to research ethics
committees and regulators why individual consent may
not be required in cluster trials when the intervention tar-
gets the cluster. We see two possible justifications. First,
ethical and regulatory requirements for informed consent
a p p l yo n l yt or e s e a r c hs u b j e cts. If it turns out that, for
instance, patients or community members who are only
indirectly impacted by the study intervention are not
research subjects, then informed consent is ipso facto not
required. Second, requirements for informed consent may
be waived if four conditions obtain: the research poses no
more than minimal risk; the rights and welfare of subjects
are not adversely affected; the research could not be car-
ried out practicably otherwise; and, when appropriate, sub-
jects will be debriefed [34]. The applicability of these
criteria to cluster trials requires further analysis to provide
researchers and research ethics committees with practical
guidance. When does a cluster trial pose only minimal risk
to subjects? When does a waiver of consent not adversely
affect the rights and welfare of research subjects? How rig-
orously are we to understand the requirement that the
research could not practicably be carried out? Must sub-
jects be debriefed and, if so, how should this be done?
When must informed consent be obtained from
healthcare workers in cluster trials? There are at least
three dimensions of this issue that require further con-
sideration. First, when the study intervention targets an
entire hospital or primary care practice it may be diffi-
cult for a healthcare worker who refuses consent to
avoid the study intervention. Second, health care work-
ers are commonly believed to have an obligation to
engage in quality improvement. Third, as Hutton and
colleagues point out, “if a health care professional
chooses not to participate in a study, they [sic]a r ei n
effect denying their patients the potential benefits of
participation. Healthcare providers ought to do the best
for their patients...” [10].
When the study intervention is administered at the
individual level, it is generally agreed that the informed
consent of the research subject must be obtained [33].
But when a cluster trial involves a behavioral interven-
tion, the informed consent process may lead to treat-
ment contamination [35,36]. Edwards and colleagues
explain that
“[i]nforming the controls fully about the experimen-
tal arm(s) is likely to produce the very effect that
randomizing by cluster was designed to avoid – that
is, prompting controls to adopt the treatment(s)
under investigation. One option is to withhold infor-
mation about the novel treatment from controls, on
the grounds that they are getting conventional care
and are therefore in the same position as people out-
side the experiment” [32].
But can information about the details of the study
intervention be withheld from research subjects in the
control arm consistent with the principle of respect for
persons?
Finally, Klar and Donner raise a difficult question
regarding the timing of informed consent that requires
further exploration. To illustrate their concern they
point to two studies examining the impact of vitamin A
administration on early childhood mortality. In the first
study, the unit of randomization was the household and
informed consent was obtained from study participants
prior to randomization [37]. In the second study, the
unit of randomization was the community and informed
consent was only obtained after randomization [38]. The
authors worry that
“[t]he relative absence of ethical guidelines for cluster
randomized trials appears to have created a research
environment in which the choice of randomization
unit may determine whether informed consent is
deemed necessary before random assignment...It
seems questionable, on both an ethical level and a
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tion should play such a critical role in deciding
whether informed consent is required [before rando-
mization]” [39].
A subsequent paper in the series examines each of
these questions in detail.
3. Does clinical equipoise apply to CRTs?
The ethical principle of beneficence obliges researchers
to not harm needlessly and, where possible, to promote
the good of research subjects. The application of benefi-
cence to cluster trials raises two broad questions.
First, do researchers have an ethical obligation to
research subjects in the control arm to provide more
than usual care? The question arises out of the belief
that, while subjects in the experimental arm may benefit
as a result of study participation, those in the control
a r ma r ee x p o s e dt or i s k sa n db u r d e n sw i t h o u tt h ep r o -
spect of such benefit. Glanz and colleagues state:
“Meeting [ethical] requirements...is particularly chal-
lenging when individuals or communities are assigned
to control or comparison groups that do not receive
t h ei n t e r v e n t i o nh y p o t h e s i z e dt ob em o s te f f e c t i v e .
The control subjects may be burdened disproportio-
nately by data collection requirements without receiv-
ing the benefit of services or resources” [36].
According to Klar and Donner, “some investigators
have attempted to ensure that these individuals can still
benefit from participation by offering a minimal level of
intervention or, alternatively, by offering all individuals
the intervention by the technique of delaying its interven-
tion in the control group” [39]. While intuitively appeal-
ing, these approaches require further reflection. If
denying research subjects in the control arm access to
the hoped for benefits of the experimental intervention is
ethically impermissible, then why is it permitted to give
them only “minimal” benefits or to delay their access to
these benefits?
Second, as data accumulate in a cluster trial, is there an
obligation to modify or stop the study if one of the inter-
ventions appears unsafe or unexpectedly effective? For a
variety of reasons, data monitoring committees are not
commonly used in cluster randomized trials. When data
monitoring committees are employed, they require clear
guidance as to their ethical obligations. Glanz and collea-
gues have argued that concerns of safety or unexpected
efficacy may require a data monitoring committee to
modify or stop a study prematurely [36]. They point out
that “interim analysis could show a clear improvement in
psychological or medical outcomes associated with an
intervention. It would then be reasonable to offer the
more effective strategy to all communities or partici-
pants” [36]. It is well recognized that early differences
between interventions may be the result of chance or
bias rather than a true intervention effect. How much
evidence of a “clear improvement” ought there be before
a data monitoring committee recommends that a study
ought to be modified or stopped?
In the literature on individually randomized trials, the
concept of clinical equipoise helpfully frames questions
regarding researcher obligations to subjects in the control
group and when data monitoring committees ought to
recommend modifying or stopping a clinical trial. As
described above, clinical equipoise permits a trial to be
started when there exists a state of honest, professional
disagreement in the community of expert practitioners as
to the preferred treatment [19]. By implication, a trial
ought to be stopped when the moral warrant for its con-
duct no longer obtains [40]. It is unclear, however,
whether clinical equipoise can be applied to cluster trials.
The concept is commonly understood as emerging from
the fiduciary relationship between physician-researcher
and patient-subject [41]. Cluster trials may involve
neither physician-researchers nor patient-subjects. For
instance, in both the NEXUS trial and the Keystone
study, the targets of the study intervention were health
care workers themselves. In the COMMIT study, the tar-
gets of the study intervention were communities and
community members. If clinical equipoise is to be used
to address issues posed by cluster trials, a moral founda-
tion relevant to cluster trials will have to be articulated
for it. The applicability of clinical equipoise to CRTs is
considered in detail in a subsequent paper in the series.
4. How do we determine if the benefits outweigh the
risks of CRTs?
The principle of beneficence requires that the benefits of
study participation stand in reasonable relation to its risks.
Numerous publications describe the variability in review
from one research ethics committee to the next. For
instance, Hearnshaw documents wide discrepancies in
requirements for ethics review and time to approval in 11
European countries for a study involving an information
pamphlet and questionnaire for elderly patients and their
physicians [42]. While part of the variation in ethics review
is a result of regulatory differences among countries, the
lack of a structured approach to the ethical analysis of risk
is thought to be an important contributing factor.
Described in detail above, component analysis provides
research ethics committees with a systematic approach
to the ethical analysis of benefits and harms in research
[18]. The applicability of component analysis to cluster
randomized trials is, unfortunately, unclear. If component
analysis is to be applied to cluster trials, a number of con-
ceptual hurdles will first have to be cleared.
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apeutic procedures hold in cluster trials? The first step
in component analysis is the demarcation of therapeutic
and nontherapeutic procedures. The distinction between
therapeutic and nontherapeutic procedures is generally
unproblematic in cluster trials with an individual level
intervention. These individual level interventions com-
monly are drug, surgical, or behavioral interventions
that aim to benefit research subjects, and, thus, they are
straightforwardly therapeutic interventions. The diffi-
culty is posed by cluster trials involving a cluster level
intervention. Public health trials commonly involve a
cluster level intervention designed to improve the health
of a community and its members. For instance, the
COMMIT trial employed a multimedia campaign to
increase quit rates in heavy smokers and reduce the pre-
valence of smoking in the community. Ought we to
understand these interventions as therapeutic? Even
more difficult to classify are complex interventions that
aim to modify healthcare worker behavior in knowledge
translation trials. The NEXUS trial used audit and feed-
back and educational messages to attempt to reduce
physician orders for needless radiographs. Should we
classify these procedures as therapeutic or nontherapeu-
tic interventions?
The second step in component analysis is to ask
whether therapeutic procedures meet the ethical stan-
dard of clinical equipoise [18]. Question #3 above consid-
ers in detail the applicability of clinical equipoise to
cluster trials. The third step in component analysis is to
ask whether the risks of nontherapeutic procedures are
minimized consistent with sound scientific design, stand
in reasonable relation to the knowledge to be gained,
and, if the study involves a vulnerable population, pose
no more than a minor increase above minimal risk [18].
The applicability of each of these standards to cluster
trials deserves exploration. Of particular interest is the
meaning of minimal risk in the context of a cluster trial.
Minimal risk is commonly defined as the risks of daily
l i f eo fah e a l t h yp e r s o n[ 4 3 ] .When cluster trials target
households, neighborhoods, or communities, it is unclear
whether an individualistic understanding of minimal risk
remains appropriate. Might minimal risk refer to the
quotidian risks faced by clusters rather than individuals?
What impact would such an understanding have on the
review of cluster trials? A subsequent paper in the series
analyzes these questions in detail.
5. How ought vulnerable groups be protected in CRTs?
The principle of justice requires that vulnerable groups in
research both be protected adequately and not unduly
denied access to research benefits. Vulnerable groups are
commonly understood to include pregnant women, pris-
oners, children, and incompetent adults, and cluster trials
have studied all of these groups. Althabe and colleagues
describe a cluster trial of a multifaceted behavioral inter-
vention to improve obstetrical care in Argentina and
Uruguay [44]. Hickman and colleagues randomized spe-
cialist drug clinics and prisons to test whether the use of
dried blood spots to test for hepatitis C would increase
uptake of diagnostic testing by injection drug users [45].
Kipping and colleagues describe a pilot cluster trial in
which schools with children 9 and 10 years of age were
randomized to receive an obesity prevention intervention
or no intervention [46]. De Smet and colleagues rando-
mized 13 intensive care units in the Netherlands to
receive digestive tract decontamination with oral and
intravenous antibiotics, digestive tract decontamination
with oral antibiotics only, and usual care in an attempt to
reduce 28-day patient mortality [47].
A variety of additional protections apply when clinical
research involves a vulnerable group. The inclusion of
the vulnerable group in research must be required to
answer the study hypothesis; a vulnerable group cannot
be used merely as a population of convenience. When
prospective research subjects are incapable of providing
informed consent, a surrogate decision maker must pro-
vide consent on their behalf. Finally, the risks of nonther-
apeutic procedures must not exceed a minor increase
above minimal risk. Cluster trials, particularly those
involving interventions applied at the level of the cluster,
may further restrict the ability of vulnerable groups (or
their surrogate decision makers) to choose research parti-
cipation freely. Does this imply that greater protections
for vulnerable groups in cluster trials are required? How
might one meaningfully enhance protections without
impeding research that may benefit the health of vulner-
able groups?
Research conducted in developing countries raises a
host of ethical issues [17]. Consider Bolton and colleagues’
description of the first cluster randomized trial of psy-
chotherapy in sub-Saharan Africa [48]. Depression is a
common and serious health problem in sub-Saharan
Africa, with a prevalence estimated at 21% [48]. Unfortu-
nately, few treatments are available for those suffering
from depression in impoverished countries. Antidepres-
sant drugs are too expensive and psychotherapy, devel-
oped for use in industrialized countries, has not been
tested for efficacy. In the trial, 30 villages in rural Uganda
were randomized to receive psychotherapy or usual care.
Study subjects were identified with the help of community
leaders, healers, and other knowledgeable persons and,
after they provided verbal informed consent, the diagnosis
of depression was confirmed with a culturally appropriate
questionnaire. In villages allocated to the intervention
arm, subjects received group-based interpersonal psy-
chotherapy for 90 minutes each week for 16 weeks. In
control villages, research subjects were free to seek out
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assessed after the intervention period. The study interven-
tion proved highly effective in treating depression: after
the intervention, 6.5% of subjects in the intervention
group met the criteria for severe depression, compared
with 54.7% of subjects in the control group. Upon comple-
tion of the study, group psychotherapy was made available
to the control communities.
The trial of interpersonal psychotherapy for depression
illustrates both the potential and challenges of cluster
trials in developing countries. Researchers conducting
cluster trials face ethical issues that flow from cultural
differences and disparities in access to health care
between host and sponsor countries. What ethical stan-
dards, including those for informed consent, ought to
apply: those of the host or sponsor country? What treat-
ment should research subjects in the control arm receive?
Clinical equipoise requires patients enrolled in a trial not
b ee x p o s e dt ot r e a t m e n tk n o w nt ob ei n f e r i o rt ot r e a t -
ments available in clinical practice. But, one might ask,
available where? In developed countries, standard treat-
ment for major depression includes antidepressant drugs
and psychotherapy. Must subjects in the control arm
receive the best, proven therapy, even if it is locally una-
vailable? In communities with substandard access to
healthcare, do researchers have an obligation to provide
research subjects with treatment for medical conditions
not related to the study condition? What obligations do
researchers and study sponsors have to research subjects
and host communities after completion of the study? Do
they have a moral obligation to provide participating
communities with access to the study intervention (if it
proves effective), and, if so, for how long? These impor-
tant justice issues are explored in a subsequent paper in
the series.
6. Who are gatekeepers and what are their
responsibilities?
There is a growing consensus in the research ethics litera-
ture that researchers have obligations to communities par-
ticipating in research. The ethical principle of respect for
communities flows from the recognition that the commu-
nity has moral worth and, as a result, researchers have a
duty to protect and promote its interests [24]. The com-
munity-researcher relationship has been described as a
partnership, in which community consultation and nego-
tiated agreement are key features [25]. When a community
has a legitimate political authority empowered to speak on
behalf of its members, researchers may additionally be
required to seek community consent to research participa-
tion. Importantly, community consent does not supplant
the requirement for individual informed consent to study
participation. While protections for communities in
research may straightforwardly apply to cluster trials in
which the unit of randomization is the community, their
applicability across the scope of cluster trials is uncertain.
Cluster trials randomize diverse groups that are not com-
munities – households, primary care practices, hospital
wards, classrooms, and neighborhoods – and whose moral
status is not well characterized. In the cluster trials litera-
ture, the gatekeeper has emerged as a key player in pro-
tecting the interests of these diverse groups and their
members [32,33,49]. However, a variety of questions
regarding the role, function, and authority of gatekeepers
have yet to be explored adequately.
Who are gatekeepers? When cluster trials involve an
intervention that is administered at the cluster level, diffi-
culties in obtaining meaningful individual informed con-
sent have led to the practice of using gatekeepers [49],
guardians [32], and cluster representation mechanisms
[33] to protect group and individual interests. Edwards
and colleagues define a gatekeeper as “an agent...who has
the power to ‘deliver’ [a] cluster,” and who acts as an
advocate on behalf of cluster interests [32]. Hutton,
defines gatekeepers as “people in either political or
administrative positions who are able to give consent for
those within a cluster to be randomized” and whose con-
sent may occur on multiple “levels” [49]. Current descrip-
tions of gatekeepers, however, do not give a clear account
of who can act as a gatekeeper when there are no clear
administrative or political structures in place. The diver-
sity of groups studied in cluster trials poses a challenge
to how we identify gatekeepers, and how group charac-
teristics influence who may serve as representatives.
What are the functions of gatekeepers? Gatekeepers are
described as being able to “deliver” [32] or “give consent
for” [49] a cluster. The U.K. Medical Research Council
guidelines describe the role of a gatekeeper as “analo-
gous...to that of individuals for individual decisions” and
says the gatekeeper must act “in the interests of the clus-
ter/individuals in the cluster” [33]. Further, the gate-
keeper must document that he or she “considers the
cluster’s participation in the trial to be in the interests of
the cluster as a whole/in the interests of each member of
the cluster (as appropriate...)” [33]. The potential for con-
flict among the various sets of interests protected by the
gatekeeper requires careful examination. Acknowledging
that community or cluster and individual interests are
separable and may be conflicting [24,50], how should a
gatekeeper balance individual and cluster interests if they
conflict? Gatekeepers, who may be in administrative posi-
tions (e.g., practice managers, hospital chief executive
officers), will also have to balance cluster and institu-
tional interests and consider the impact of the research
on the organization for which they are responsible.
What are the sources of a gatekeeper’s authority? One of
the outcomes of the debate on community consent is the
recognition of the importance of the issue of authority
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authority empowered to speak on behalf of its members
may provide community consent. The issue of authority
for the variety of functions ascribed to gatekeepers
requires careful scrutiny. When does a gatekeeper possess
the authority to consent on behalf of the cluster? When
individual consent cannot be obtained, does a gatekeeper
have the authority to consent on behalf of the individuals
in the cluster? A subsequent paper in the series critically
appraises the role, function, and authority of gatekeepers
in CRTs.
Conclusion
The cluster randomized trial is used increasingly in
knowledge translation research, quality improvement
research, community based intervention studies, public
health research, and research in developing countries.
However, cluster trials raise difficult ethical issues that
challenge researchers, research ethics committees, regu-
lators, and sponsors as they seek to fulfill responsibly
their respective roles. Our project will provide a sys-
tematic analysis of the ethics of cluster trials. Here we
have outlined a series of six areas of inquiry that must
be addressed if the cluster trial is to be set on a firm
ethical foundation. Subsequent papers in this series will
address each of these areas, clarifying the ethical issues
at stake and, where possible, arguing for a preferred
solution. Our hope is that these papers will serve as the
basis for the creation of international ethical guidelines
for the design and conduct of cluster randomized trials.
Note
We have created a Wiki webpage to facilitate an open
discussion about the ideas expressed in this and other
papers published in the series on ethical issues in CRTs.
Please enter your thoughts and comments at http://
crtethics.wikispaces.com.
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